AxoGen (AXGN) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for AxoGen (NASDAQ: AXGN):

• 10/31/2026 – AxoGen was upgraded by Wall Street Zen from “hold” to “strong-buy”.
• 10/29/2026 – AxoGen had its price target raised by Leerink Partners from $52.00 to $56.00. They now have an “outperform” rating on the stock.
• 10/29/2026 – AxoGen had its “buy” rating reaffirmed by Lake Street Capital. They now have a $58.00 price target on the stock.
• 10/29/2026 – AxoGen had its price target raised by Barclays from $50.00 to $60.00. They now have an “overweight” rating on the stock.
• 10/29/2026 – AxoGen had its “outperform” rating reaffirmed by Raymond James Financial. They now have a $57.00 price target on the stock.
• 10/29/2026 – AxoGen had its price target raised by Canaccord Genuity Group from $55.00 to $60.00. They now have a “buy” rating on the stock.
• 10/29/2026 – AxoGen had its price target raised by Truist Financial from $53.00 to $60.00. They now have a “buy” rating on the stock.
• 10/29/2026 – AxoGen had its price target raised by Wells Fargo & Company from $48.00 to $56.00. They now have an “overweight” rating on the stock.
• 10/29/2026 – AxoGen had its price target raised by HC Wainwright from $53.00 to $56.00. They now have a “buy” rating on the stock.
• 10/28/2026 – AxoGen had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $60.00 price target on the stock.
• 10/28/2026 – AxoGen was given a new $65.00 price target by Mizuho.
• 10/23/2026 – AxoGen had its price target lowered by Barclays from $55.00 to $50.00. They now have an “overweight” rating on the stock.
• 10/12/2026 – AxoGen is now covered by Bank of America. They set a “buy” rating and a $52.00 price target on the stock.
• 10/6/2026 – AxoGen is now covered by Barclays. They set an “overweight” rating and a $55.00 price target on the stock.
• 10/6/2026 – AxoGen was upgraded by Barclays to “strong-buy”.
• 10/5/2026 – AxoGen had its “buy” rating reaffirmed by Lake Street Capital.
• 10/1/2026 – AxoGen had its price target lowered by Truist Financial from $60.00 to $53.00. They now have a “buy” rating on the stock.
• 10/1/2026 – AxoGen had its price target lowered by Truist Financial from $60.00 to $53.00. They now have a “buy” rating on the stock.
• 9/29/2026 – AxoGen was downgraded by Morgan Stanley to “hold”.
• 9/26/2026 – AxoGen was downgraded by Wall Street Zen from “buy” to “hold”.
• 9/25/2026 – AxoGen had its price target raised by Raymond James Financial from $48.00 to $53.00. They now have an “outperform” rating on the stock.

AxoGen Stock Up 0.6%

AXGN traded up $0.32 during midday trading on Tuesday, reaching $50.16. 362,205 shares of the company were exchanged, compared to its average volume of 1,204,602. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.04 and a current ratio of 6.60. The company’s fifty day moving average price is $42.84 and its 200 day moving average price is $39.54. The company has a market cap of $2.70 billion, a price-to-earnings ratio of -77.18 and a beta of 1.17. AxoGen, Inc. has a one year low of $22.92 and a one year high of $52.91.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.21 EPS for the quarter, topping the consensus estimate of $0.13 by $0.08. The firm had revenue of $75.83 million during the quarter, compared to the consensus estimate of $73.45 million. AxoGen had a negative return on equity of 7.18% and a negative net margin of 11.96%. As a group, analysts expect that AxoGen, Inc. will post -0.44 EPS for the current year.

Insider Buying and Selling

In other AxoGen news, Director Joseph A. Tyndall sold 3,500 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $49.70, for a total value of $173,950.00. Following the completion of the sale, the director directly owned 10,650 shares of the company’s stock, valued at approximately $529,305. This represents a 24.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathy Weiler sold 14,150 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $45.30, for a total transaction of $640,995.00. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 98,503 shares of company stock valued at $4,656,947 in the last 90 days. Insiders own 2.44% of the company’s stock.

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.